Results of the Annual General Shareholder Meeting as of June 13, 2023
15 June 2023 - 3:00PM
Results of the Annual General Shareholder Meeting as of June 13,
2023
Results of the Annual General Shareholder
Meeting as of June 13, 2023
Paris, France, June
15, 2023 –
07:00 CET – The Annual General Shareholder Meeting of
Pixium Vision SA (Euronext Growth Paris - FR0011950641 - Mnemo:
ALPIX), a bioelectronics company that develops innovative bionic
vision systems to enable patients who have lost their sight to live
more independent lives, met in Paris on June 13, 2023, and adopted
all the resolutions put to the vote. These included the approval of
the consolidated and the parent company financial statements, the
renewal of the appointments of Mr. Bernard Gilly and Mr. Lloyd
Diamond, the renewal of the share buyback program, the granting of
a delegation to issue share subscription warrants (BSA), amendments
to the bylaws, and the continuation of business following the
recognition of the loss of half of shareholders' equity. The
detailed results of the vote are available on the Company's website
(www.pixium-vision.com).
The Board of Directors meeting held after this Combined General
Meeting reappointed Mr. Bernard Gilly as Chairman of the Board of
Directors.
Mr. Lloyd Diamond's term of office as Chief Executive Officer
was renewed by decision of the Board of Directors on February 16,
2023.
Pixium Vision's Board of Directors remains composed of the
following members:
- Mr. Bernard Gilly, Chairman of the Board of Directors
- Mr. Lloyd Diamond, Chief Executive Officer and Director
- BPIfrance Participations, represented by Ms. Olivia Le Proux de
la Rivière, Director
- Sofinnova Partners, represented by Mr. Gérard Hascoët,
Director
- Ms. Marie-Hélène Meynadier, independent Director
- Ms. Anja Krammer, independent Director
- Mr Joseph August Moretti,
independent Director
About Pixium Vision
Pixium Vision is creating a
world of bionic vision for those who have lost their sight,
enabling them to regain visual perception and greater autonomy.
Pixium Vision’s bionic vision systems are associated with a
surgical intervention and a rehabilitation period. Prima System
sub-retinal miniature photovoltaic wireless implant is in clinical
testing for patients who have lost their sight due to outer retinal
degeneration, initially for atrophic dry age-related macular
degeneration (dry AMD). Pixium Vision collaborates closely with
academic and research partners, including some of the most
prestigious vision research institutions in the world, such as
Stanford University in California, Institut de la Vision in Paris,
Moorfields Eye Hospital in London, Institute of Ocular Microsurgery
(IMO) in Barcelona, University hospital in Bonn, and UPMC in
Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies
as “Entreprise Innovante” by Bpifrance.
Forward-Looking Statements. This press release
contains certain forward-looking statements. Although the Company
believes its expectations are based on reasonable assumptions,
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. For a discussion of risks and
uncertainties which could cause the Company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors (“Facteurs de Risques”) section of the Company’s
2022 Half-Year Financial Report and other documents the Company
files with the AMF, which is available on the AMF website (www.amf-
france.org) or on the Company’s website.
For more information:
http://www.pixium-vision.com/fr
Follow us on @PixiumVision;
www.facebook.com/pixiumvision
www.linkedin.com/company/pixium-vision
For more information:
http://www.pixium-vision.com/fr
Follow us on @PixiumVision;
www.facebook.com/pixiumvision
www.linkedin.com/company/pixium-vision
Contacts
Investor
RelationsPixium VisionOffer NonhoffChief
Financial Officerinvestors@pixium-vision.com |
Media
Relations Rose Piquante
ConsultingSophie
BaumontSophie.baumont@rosepiquante-consulting.com+33 6 27 74 74
49 |
- Pixium Vision - AG 13.06.2023 - CP Post Ag - EN- V1
Pixium Vision (EU:ALPIX)
Historical Stock Chart
From May 2024 to Jun 2024
Pixium Vision (EU:ALPIX)
Historical Stock Chart
From Jun 2023 to Jun 2024